Clinical trials of vaccines differ from those of drugs and can pose additional challenges due to disease seasonality.
-
Date Time 11:00 - 12:00
Location Webinar Timezone America/New York
Overview
Seasonal studies present unique challenges to ensure successful execution, enrollment in advance of the season, and thorough disease surveillance.Join us for this webinar to learn best practices and considerations for effective execution of seasonal vaccine studies. Get insights from four seasonal vaccine efficacy case studies that demonstrate best practices across the duration of the study; from country and site identification, through enrollment and surveillance to database lock.
Topics covered include:
- Study planning
- Achievement of study start up/regulatory activities to activate all sites simultaneously
- Creative execution of risk based activities
- Importance of aggressive disease surveillance
- Acquisition of quality data
- Leveraging technologies that enhance data quality
Audience
- Clinical operations staff (VPs, Directors, PMs, CTMs, CRAs)
- Staff supporting site start up
- Management staff overseeing seasonal studies
- Other operational staff of all levels (Data Management, IWRS, Labs, ePRO, Clinical/Non-Clinical Supply, etc.)
On-Demand Webinar Archive
To access the archived recording of this webinar, visit our webinar channel and complete a one time only form. This will give you access to our entire library of archived webinars.
Presenters
Michele Brotherton
Michele has over 28 years of clinical research experience in the laboratory, pharmaceutical and CRO industries, and 20 years of tenure with 91黑料. She has spent the last 14 years focused exclusively in vaccines clinical development. Her vaccine therapeutic expertise includes seasonal and pandemic influenza, meningococcal, pneumococcal, herpes zoster, anthrax, RSV, and small pox. She has extensive clinical and project management expertise encompassing Phase II-III studies for pharma and government clients immunizing 200 to over 13,000 participants in healthy adult, elderly, and pediatric populations. Her experience includes the strategic oversight of vaccine portfolios.